Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.25%. A quarter ago, it was expected that this company would post a loss of $0.68 per share when it actually produced a loss of $0.60, delivering a surprise of 11.76%.Over the last four quarters, the company ...

Tarsus Pharmaceuticals (TARS) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 day, ladies and gentlemen, and thank you for standing by. Welcome to the Tarsus First Quarter twenty twenty five Earnings Conference Call. At this time, participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. As a reminder, this conference call is being recorded. At this time, I would like to turn the conference over to Mr. David Nacasone. Sir, please begin. Sp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to ____. Commission File Number: 001-39614 TARSUS PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 81-4717861 ...

Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements Generated $78.3 million in net product sales of XDEMVY , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients ® Strengthened financial position with approximately $135 million raised in public equity of ering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner o ...

Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to h ...

Tarsus Pharmaceuticals, Inc. (TARS) closed the last trading session at $50.90, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $67.13 indicates a 31.9% upside potential.The mean estimate comprises eight short-term price targets with a standard deviation of $13.74. While the lowest estimate of $41 indicates a 19.5% decline from the current price level, the most optimist ...

IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceut ...

IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif. "From new prevalence data in Japan ...

文章核心观点 - 公司宣布定价并进行普通股公开发行，预计获得约1.25亿美元毛收入，介绍了发行相关安排及公司业务情况 [1][6] 发行情况 - 公司宣布公开发行2,808,988股普通股，定价每股44.50美元，承销商有30天选择权可额外购买最多421,348股 [1] - 发行毛收入预计约1.25亿美元，不包括承销商行使额外购买选择权，预计3月14日完成发行，需满足惯例成交条件 [1] 发行管理 - 高盛、美银证券、巴克莱和奥本海默担任此次发行的联席账簿管理人 [2] 注册声明与招股书 - 发行股票的注册声明于2024年2月29日提交给美国证券交易委员会并自动生效，可通过SEC网站获取 [3] - 初步招股书补充文件已提交给SEC，可在SEC网站获取，最终招股书补充文件和招股书可从相关机构获取 [4] 公司业务 - 公司应用科学和新技术革新患者治疗，从眼科护理开始，推进管线以解决多个治疗领域未满足需求的疾病 [6] - 公司的XDEMVY获FDA批准用于治疗蠕形螨睑缘炎，还在开发TP - 04治疗眼部酒渣鼻和TP - 05预防莱姆病 [6] 联系方式 - 媒体联系人是Adrienne Kemp，电话(949) 922 - 0801，邮箱AKemp@tarsusrx.com [8] - 投资者联系人是David Nakasone，电话(949) 620 - 3223，邮箱DNakasone@tarsusrx.com [8]

文章核心观点 - 公司宣布开始承销公开发行1亿美元普通股，并拟授予承销商30天选择权，可额外购买最多1500万美元普通股 [1] 公司业务 - 公司应用成熟科学和新技术革新患者治疗，从眼科护理开始，推进管线以解决多个治疗领域中未满足需求高的疾病，包括眼科护理和传染病预防 [5] - 公司的XDEMVY（0.25%洛替拉纳滴眼液）获美国FDA批准用于治疗蠕形螨睑缘炎，还在开发用于潜在治疗眼部酒渣鼻的TP - 04和用于潜在预防莱姆病的口服片剂TP - 05 [5] 发行相关 - 此次发行的联席账簿管理人包括高盛集团、美国银行证券、巴克莱和奥本海默公司 [2] - 与拟发售股份相关的注册声明于2024年2月29日提交给美国证券交易委员会并自动生效，发售将仅通过招股说明书进行，初步招股说明书补充文件将提交给美国证券交易委员会并可在其网站获取，也可从联席账簿管理人处获得 [3] 联系方式 - 媒体联系人是企业传播高级总监Adrienne Kemp，电话(949) 922 - 0801，邮箱akemp@tarsusrx.com [7] - 投资者联系人是投资者关系主管David Nakasone，电话(949) 620 - 3223，邮箱DNakasone@tarsusrx.com [7]